·211
In 211, Harbin Pharmaceutical Group withstood unprecedented severe tests and strived to maintain steady economic development. Over the past year, the Group has closely focused on the established goals, fully implemented the "six strategies", accelerated the integration of internal resources and the construction of key projects, and achieved a year-on-year increase of 7.45% in sales revenue, reaching a new record high.
(a) actively promote marketing innovation, market expansion has achieved initial results.
Harbin Pharmaceutical Group regards marketing management as the top priority of all its work, and has made active explorations and bold innovations in structural adjustment, product sorting and secondary development of old products. Through the implementation of marketing information project construction and the dispatch of market supervisors, a rapid response mechanism closer to the market has been established, market supervision and assessment have been strengthened, and the control ability of key links such as channel, flow direction and payment recovery has been further improved. Sanjing Pharmaceutical Co., Ltd., Harbin Pharmaceutical No.6 Factory and Chinese Medicine Co., Ltd. have made good achievements by strengthening the construction of OTC team, strengthening the maintenance of terminal market, integrating the resources of primary agents and secondary distributors, constantly expanding terminal channels, and focusing on the sales of key incremental products. In 211, the sales revenue of 61 large-scale superior varieties produced by the Group increased by 4.3% year-on-year.
(2) accelerate the pace of scientific and technological innovation and lay the foundation for comprehensive integration of scientific and technological resources.
In order to continuously promote the "integrated" operation of scientific and technological innovation, Harbin Pharmaceutical Group established the Harbin Pharmaceutical Group Pharmaceutical Research Institute, identified a number of key R&D products in the fields of anti-tumor, cardiovascular and biopharmaceuticals, concentrated superior resources, intensified research efforts, and achieved phased results. The new product cefmetazole sodium and its preparation of Harbin Pharmaceutical General Factory won the first prize of scientific and technological progress in Heilongjiang Province. In 211, the Group * * * obtained the production approval number for 17 new products, including live porcine blue ear disease vaccine. Among them, gemcitabine hydrochloride for injection, which was developed by Pharmaceutical Research Institute and declared by Harbin Pharmaceutical Bio-declaration, is the first batch of imitation anti-tumor drugs in China with quality standards completely in line with USP, which indicates that the Group has made new progress in the research and development of high-quality generic drugs. Harbin Pharmaceutical Co., Ltd., Sanjing Pharmaceutical Co., Ltd., Harbin Pharmaceutical Biological Co., Ltd. and Harbin Pharmaceutical Vaccine Co., Ltd. successfully passed the accreditation review of high-tech enterprises, and Harbin Pharmaceutical Biological successfully passed the on-site inspection of the new GMP certification, becoming the first certified enterprise in the province.
(3) actively promote asset reorganization and management integration to improve the quality of enterprise operation.
Harbin Pharmaceutical Co., Ltd. acquired all the shares of Harbin Pharmaceutical Bio-and Sanjing Pharmaceutical held by Harbin Pharmaceutical Group through non-public offering of shares to Harbin Pharmaceutical Group, promoted asset restructuring and integrated medical platform resources. At present, the restructuring plan has been approved by the China Securities Regulatory Commission. This marks that Harbin Pharmaceutical Group has fully fulfilled its commitment to share reform, and has successfully listed the pharmaceutical assets of the group company as a whole, greatly improving the capital operation and industry integration ability of Harbin Pharmaceutical Co., Ltd., laying a solid foundation for Harbin Pharmaceutical Group to further implement strategic capital expansion.
21
The 11th Five-Year Plan period is an extraordinary five years in the development history of Harbin Pharmaceutical Group. In the past five years, faced with the adverse factors such as the international financial crisis, the Group has fully implemented the innovative development strategy, realized the fundamental adjustment of the property right structure by introducing capital, turned the "bottleneck" of development into a competitive advantage, made every effort to promote the sound and rapid development of the Group's economy, and successfully completed all the tasks set out in the Eleventh Five-Year Plan. With great ideas, boldness and generosity, "Harbin Pharmaceutical" has drawn a gratifying and proud economic growth curve, showing the Group. From 26 to 21, the group's main business income doubled (compound annual growth rate of 15%), profits and taxes increased by 1.21 times (compound annual growth rate of 17.2%) and profits increased by 2.35 times in five years, and the comprehensive economic strength of the group was significantly enhanced. This indicates that with the concerted efforts of all Harbin Pharmaceutical Workers, we have successfully achieved the planning and development goal of "building a new Harbin Pharmaceutical Factory" during the 11th Five-Year Plan period, and exceeded the strategic task of "benefit index outperforming the market" issued by the board of directors of the Group.
-this is five years of becoming one of the top pharmaceutical companies in the world. Harbin Pharmaceutical Group's position in the industry has been significantly improved, and its scale strength ranks among the top 5 pharmaceutical companies in the world. It has been ranked as the top 1 pharmaceutical enterprises in China for five consecutive years, and has been selected as the top three OTC drug manufacturers in China for five consecutive years. It has been among the top ten industrial enterprises in the province for five consecutive years, and the economic scale of Harbin Pharmaceutical Group has reached more than 7% of the total economic output of the pharmaceutical industry in the province. Harbin Pharmaceutical Group has become one of the indispensable important economic supports for Harbin's economic and social development.
-this is five years to accelerate the transformation of economic development mode. By implementing large-scale project construction and promoting the development of emerging industries, the Group's economic operation quality and industrial energy level have reached a new level. Over the past five years, the Group has invested a total of 1.349 billion yuan and implemented 31 technological transformation projects. Up to now, 19 projects in * * * have been completed and put into production, with a cumulative increase of 1.5 billion yuan in sales revenue and 3 million yuan in new profits.
-this is five years of development through innovation. In the past five years, through the implementation of technological innovation, the Group has obtained 6 approvals for new products, and another 55 varieties are under research, among which 6 varieties under research are national first-class new drugs. Accumulated 89 patents authorized by the state; * * * 129 varieties have passed the national high-tech product certification. At present, the number of varieties with annual sales income exceeding 1 million yuan has reached 59, of which 22 varieties have sales scale exceeding 1 million yuan.
-This is the five years of shaping the image of a world-class new Harbin medicine. The influence and brand value of "Harbin Pharmaceutical" brand have hit record highs. The brand value of "Harbin Pharmaceutical" has increased from 1.635 billion yuan in 26 to 16.62 billion yuan, winning the title of the most valuable brand in China pharmaceutical industry for five consecutive years, and being shortlisted as one of the "Top 5 Chinese power brands that have influenced the world"; The total evaluation value of four well-known trademarks in China, which were selected as "Top 1 Asian Brands", "Harbin Pharmaceutical", "Sanjing", "Shiyitang" and "Gaizhonggai", has exceeded 3 billion yuan, creating a huge intangible asset value. At present, the group has four international registered trademarks, such as "Harbin Pharmaceutical" and "Shiyitang", and the number of dominant brands ranks first in the national pharmaceutical industry. In the past five years, Harbin Pharmaceutical Group has spent 25 million yuan to support and participate in social welfare, and won the honorary titles of "Love Donation Award" and "National Excellent Enterprise with Harmonious Labor Relations" by the Ministry of Civil Affairs. In the society, the image of Harbin Pharmaceutical Group as a big enterprise, a big brand, honest and responsible corporate citizen has been further established.
29
The past year of 29 was the most severe year for Harbin Pharmaceutical Group since the new century. It was the year in which the medical reform policy and macroeconomic fluctuations caused the strongest impact and pressure on the production and operation of the enterprise. It was also the year in which the management team and internal structure of the enterprise were deeply adjusted and the resources were integrated to the greatest extent. It was also the year in which the tactical transformation was implemented, and the ability of the enterprise to "resist pressure and cold" was enhanced the fastest.
in the face of the dual pressures of the financial crisis and the adjustment of medical policies, we take "maintaining growth, adjusting structure, grasping projects and promoting upgrading" as the main line, turn "crisis" into "opportunity", constantly optimize the product and industrial structure, do everything possible to overcome the unfavorable factors of non-strategic capital expansion and slow growth of internal economic stock, write a brilliant chapter with courage and boldness, and the group economy presents a total expansion, structural optimization and accelerated growth. According to incomplete statistics, in 29, the industrial added value of the group company increased by 12.16% year-on-year; Operating income increased by 17.91% year on year; Profits increased by 15.5% year-on-year, among which the growth rate of operating income was higher than the average growth rate of the top 25 pharmaceutical listed companies in China by 6 percentage points, and the profit growth rate was 4 percentage points ahead. Since the establishment of Harbin Pharmaceutical Group in 1989, the comprehensive economic benefits of the group have been ranked first among pharmaceutical enterprises in Heilongjiang Province for 2 consecutive years. Since 25, the profit index and brand value have ranked first among 4,738 pharmaceutical enterprises in China for five consecutive years. In 29, the brand evaluation value of Harbin Pharmaceutical reached 15.19 billion yuan, an increase of 67 million yuan over the same period of last year, ranking among the top 5 Asian brands.
Practice has proved that we should pay attention to strategic planning, tactical coordination, be broad-minded and quick-witted, discover and cultivate favorable factors from adversity, and prepare for a rainy day at the beginning of a crisis; When the crisis strikes, decisive action should be taken, combining maintaining growth with expanding domestic demand and restructuring, highlighting the three key words of integration, innovation and management in the "Harbin Pharmaceutical Thought" to deal with the impact, and taking the road of scientific development that adapts to the characteristics of Harbin Pharmaceutical Group is the key to the group's economic rise against the trend and continuous success in 29.
first, aim at a goal, integrate superior resources, and create a new pattern of industrial cluster development. On the one hand, we insist on actively absorbing and striving for the industrial transfer of multinational pharmaceutical enterprises with a professional and intensive industrial development cooperation platform, and promoting the upgrading of the pillar industries of the Group with external increments. At present, the Group has signed a letter of intent with world-renowned multinational pharmaceutical companies to operate high-end cephalosporin varieties, and plans to establish a long-term strategic cooperative relationship to jointly promote the accelerated development of China's antibiotic industry, which has opened the prelude for Harbin Pharmaceutical Group to cooperate with world-class peers. The Chinese Medicine Company successfully increased its capital to hold Baichuan Pharmaceutical Co., Ltd. in Shangqiu, Henan Province, and thus realized the coverage of the enterprise sales network in the Central Plains. The medicinal material base of Baichuan Pharmaceutical Co., Ltd. will also play a role in the supply of main production raw materials for Chinese medicine companies, further expanding the industrial chain of Chinese medicine. On the other hand, we should re-examine the group's internal resource endowment from the perspective of sustainable development, implement the development strategy of production and operation specialization, proceed from the overall interests of the group, gradually rationalize the division of labor and cooperation within the group's industrial chain, and become stronger and more refined in the core areas. The group's internal resource integration project has achieved phased results, achieving complementary advantages, resource sharing, intensive management and low-cost operation, and strengthening the industrial chain of the main business of health care products and direct sales sectors.
the second is to seize a main line, strengthen independent innovation, and form a new bright spot of subsequent scale advantage varieties. In view of the market opportunities and demands brought by the new medical reform policy, we will accelerate the reserve and research and development of competitive products with great market potential and high technical barriers, increase investment in scientific research and development, and plan to openly invite public tenders to introduce a number of important technologies, products and standards with independent intellectual property rights. * * * involves 9 major fields and more than 6 categories, and the scale and quantity are the highest in the history of the group. With the strict requirements of the SFDA for the registration of new drugs, the Group obtained seven approvals for the production of new drugs, and 7 new products were under research and 16 new products were pending approval. Ceftian hydrochloride raw materials and preparations of Harbin Pharmaceutical General Factory were awarded the certificate of "National Key New Product"; Sanjing Pharmaceutical's "New Oral Sustained-release Preparation and Technology Platform Project" and Harbin Pharmaceutical Biological Company's "Innovative Anti-tumor Drug-Recombinant Endostatin 3 Peptide Development Project" were included in the "National Major New Drug Creation Project". With the powerful engine of the implementation of major special projects of science and technology of the Ministry of Science and Technology, the group's scientific and technological innovation system, new drug research and development, new product pilot test and industrialization will surely get greater development.
the third is to adhere to a principle, popularize excellent management and activate new impetus to speed up and increase efficiency. Starting with mechanism innovation, we constantly eliminated "management shortcomings" by strengthening internal control, and made important progress in internal control construction, quality risk control, cost control, safety production management, and management of senior leading cadres. In order to integrate the resources of the internal procurement channels of the Group, the Group established the bidding and purchasing department, further standardized the bidding and purchasing procedures for bulk materials and media advertisements, promoted the centralized management of the internal raw material procurement of the Group step by step, and carried out the "Double Excellent Sunshine Procurement" project in depth, saving the procurement cost by 451 million yuan throughout the year. By strengthening cash flow, comprehensive budget and centralized financial control of the Group, the role of the four "cash pools" of the Group Company, Harbin Pharmaceutical Co., Ltd., Sanjing Pharmaceutical Co., Ltd. has been further brought into play, which has effectively improved the ability of enterprises to control funds and the quality of operation.
The stormy year of 29 has passed. In the "examination room" to face the financial crisis, Harbin Pharmaceutical Group is firm and calm, marching forward in the storm, standing firm in the storm, overcoming serious difficulties and completing arduous tasks, and handing over an excellent answer sheet.